Le médicament du mois. Ertugliflozine seule et en combinaisons fixes : «la passe de trois» pour ce nouvel inhibiteur des SGLT2.

Scheen, André

Article (Scientific journals)

Scheen, André

2020 • In Revue Médicale de Liège, 75 (9), p. 626-632

Peer reviewed

Permalink
https://hdl.handle.net/2268/250835

PubMed
32909416

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

14 MM SCHEEN Ertugliflozine .pdf

Publisher postprint (1.08 MB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Ertugliflozin; Metformin; SGLT2 inhibitor; Sitagliptin; VERTIS; 4 inhibitor; DPP; Type 2 diabetes

Abstract :

[en] Ertugliflozin is a new sodium-glucose cotransporter type 2 inhibitor (SGLT2i) that is indicated in the treatment of type 2 diabetes. It has been investigated in the large phase 3 development programme VERTIS, in monotherapy and in association with different antidiabetic medications, including insulin. The add-on of ertugliflozin to metformin (VERTIS MET) and the association ertugliflozin-sitagliptin (VERTIS-SITA, VERTIS FACTORIAL, VERTIS SITA2) showed a significant reduction in glycated haemoglobin, without hypoglycaemia, together with a diminution of body weight and arterial blood pressure. As expected, more genital mycotic infections were observed, the only adverse event consistently reported. The cardiovascular safety of ertugliflozin has been demonstrated in VERTIS CV. Ertugliflozin is commercialized with two doses 5 mg and 15 mg. This SGLT2i is also available in fixed-dose combinations, ertugliflozin-metformin and ertugliflozin-sitagliptin. The three presentations offer a greater flexibility to the practitioner to optimize therapeutic choices for a complex disease where the treatment should be individualized according to the patient profile.

Disciplines :

Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Le médicament du mois. Ertugliflozine seule et en combinaisons fixes : «la passe de trois» pour ce nouvel inhibiteur des SGLT2.

Alternative titles :

[en] Ertugliflozin alone and in fixed-dose combinations : «pass of three»

Publication date :

2020

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

626-632

Peer reviewed :

Peer reviewed

Available on ORBi :

since 11 September 2020

Statistics

Number of views

131 (3 by ULiège)

Number of downloads

102 (4 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen AJ, Paquot N. Extension des indications pour les antidiabétiques avec protection cardio-rénale dans les dernières recommandations internationales pour la prise en charge du patient diabétique de type 2. Rev Med Liege 2020; 75:233-9.
Scheen AJ, Paquot N. Une révolution dans le traitement du diabète de type 2 : des antidiabétiques dotés d'une protection cardio-rénale indépendamment du contrôle glycémique ! Rev Med Liege 2020; 75:392-8.
Scheen AJ. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 Aug 27. doi: 10.1038/s41574-020-0392-2.
Scheen AJ. Canagliflozine (Invokana®) : inhibiteur des cotransporteurs rénaux SGLT2 pour traiter le diabète de type 2. Rev Med Liege 2014; 69:692-9.
Scheen AJ. Empagliflozine (Jardiance®) : nouvel inhibiteur des cotransporteurs rénaux SGLT2 comme traitement du diabète de type 2. Rev Med Liege 2015; 70:472-9.
Scheen AJ. Dapagliflozine (Forxiga®) Inhibiteur des cotransporteurs rénaux SGLT2, nouvel agent anti-hyperglycemiant dans le diabète de type 2. Rev Med Liege 2016; 71:463-9.
Scheen AJ. A propos de l'expérience belge avec les inhibiteurs des SGLT2. Med Mal Metab 2020; 14:320-30.
Markham A. Ertugliflozin: First Global Approval. Drugs 2018; 78:513-9. 9. Fediuk DJ, Nucci G, Dawra VK, et al. Overview of the clinical pharmacology of ertugliflozin, a novel sodium-glucose cotransporter 2 (SGLT2) inhibitor. Clin Pharmacokinet 2020; 59:949-65.
Scheen AJ. Pharmacodynamics, efficacy and safety of sodiumglucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 2015; 75:33-59.
Scheen AJ. Drug-drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet 2014; 53:295-304.
Scheen AJ. Combinaison fixe sitagliptine-metformine (Janumet ®). Rev Med Liege 2010; 65:648-54.
Scheen AJ. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opin Drug Saf 2018; 17:837-48.
Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 2018; 20:520-9.
Gallo S, Charbonnel B, Goldman A, et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 2019; 21:1027-36.
Frias JP. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab 2019; 14:75-83.
Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol 2016; 12:1407-17.
Scheen AJ, Paquot N. Combinaison gliptine-gliflozine dans le traitement du diabète de type 2. Rev Med Suisse 2016; 12:1384-8.
Scheen AJ, Van Gaal LF. Sitagliptine (Januvia®). Incrétinopotentiateur indiqué comme insulinosécrétagogue dans le traitement du diabète de type 2. Rev Med Liege 2008; 63:105-9.
Scheen AJ, Van Gaal LF. La sitagliptine dans le traitement du diabète de type 2 : le point cinq ans apres sa commercialisation. Rev Med Liege 2013; 68:504-10.
Scheen AJ, Paquot N. TECOS : confirmation de la sécurité cardiovasculaire de la sitagliptine. Rev Med Liege 2015; 70:511-6.
Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther 2018; 9:253-68.
Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab 2018; 20:1111-20.
Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab 2018; 20:530-40.
Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 2018; 206:11-23.
Cannon C. VERTIS CV : cardiovascular and renal outcomes. Présentation au congrès de l'American Diabetes Association, Chicago, 16 juin 2020. https://www.acc.org/education-andmeetings/ image-and-slide-gallery/media-detail?id=307A7E10 3BC04A588A3370709253FC35.
Scheen AJ. Protection cardio-rénale avec les inhibiteurs des SGLT2 : d'EMPA-REG OUTCOME à VERTIS CV. Rev Med Suisse 2020; 16:1483-8.
Patel S, Hickman A, Frederich R, et al. Safety of ertugliflozin in patients with type 2 diabetes mellitus: pooled analysis of seven phase 3 randomized controlled trials. Diabetes Ther 2020; 11:1347-67.
Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 2019; 18:295-311.
Paquot N, Scheen AJ. Ajout d'un inhibiteur de la DPP-4 ou des SGLT2 après échec d'une monothérapie par metformine chez le patient diabétique de type 2. Rev Med Suisse 2017; 13:1410-5.
Scheen AJ. Comment je traite ... un patient diabétique de type 2 mal contrôlé sous une combinaison metformine plus gliptine. Rev Med Liege 2019; 74:443-50.
Scheen AJ. Combinaison «inhibiteur des SGLT2-agoniste des récepteurs du GLP-1» pour traiter le diabète de type 2. Rev Med Suisse 2019; 15:1436-41.